German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer treatments.

BioNTech BNTX 1.61 % increase; green up pointing triangle will acquire all shares of CureVac CVAC 0.93 % increase; green up pointing triangle after the two sides reached an agreement in a deal ...

See the latest BioNTech SE ADR stock price (BNTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

BioNTech said Thursday it would buy CureVac, its onetime competitor in the Covid-19 vaccine race, for about $1.25 billion in an all-stock transaction.

Review the current BioNTech SE ADR (BNTX:XNAS) dividend yield and history to decide if BNTX is the best investment for you.

BioNTech will pay OncoC4 $200 million up front and get global rights to its drug. Privately held OncoC4 could earn milestone payments, plus royalties if the research leads to a commercialized product.

Moderna is suing fellow vaccine developers Pfizer and its German partner BioNTech, accusing it of infringing on patents related to mRNA technology used in their COVID-19 vaccine, the company ...

BioNTech SE, in collaboration with Genentech, Inc., is conducting a Phase II study titled ‘A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX ...

Moderna is not asking that courts take the Pfizer-BioNTech COVID-19 vaccine off the market or to stop future sales, in view of the public need for the vaccines.

Shares of BioNTech fell 5.7% on Monday. Vaccine stocks are volatile after Moderna’s updated revenue guidance for 2025, which fell below analyst expectations. Market-moving news hits Benzinga Pro ...

BioNTech is bolstering its artificial intelligence and machine learning capabilities through the £362 million acquisition of InstaDeep, a startup whose technology has already supported the ...